What is Leerink Partnrs' Forecast for STOK FY2029 Earnings?

Key Points

• Leerink Partners reduced their FY2029 earnings per share estimate for Stoke Therapeutics to $0.30, down from $0.35, while the consensus estimate for the current year is a loss of ($2.01) per share.
• The stock has seen mixed ratings with six analysts giving it a "buy" rating and two a "strong buy," while the average price target is $25.17.
• Stoke Therapeutics reported a quarterly loss of ($0.40) per share, which was better than analysts' expectations, and had revenue of $13.82 million versus the estimated $31.51 million.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Leerink Partnrs cut their FY2029 earnings per share estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $0.30 for the year, down from their prior estimate of $0.35. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.

STOK has been the subject of several other research reports. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They issued a "buy" rating and a $30.00 price target for the company. Wedbush lifted their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. HC Wainwright cut their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.17.

Stoke Therapeutics Trading Down 1.0%

Shares of NASDAQ STOK traded down $0.17 during trading on Thursday, reaching $16.74. 470,817 shares of the company traded hands, compared to its average volume of 782,526. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $17.61. The firm's fifty day simple moving average is $12.28 and its 200 day simple moving average is $10.06. The stock has a market cap of $913.84 million, a P/E ratio of 19.97 and a beta of 1.15.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a return on equity of 19.41% and a net margin of 26.25%.

Insider Activity

In other news, insider Barry Ticho sold 4,504 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the sale, the insider directly owned 16,775 shares of the company's stock, valued at $215,055.50. The trade was a 21.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 12,720 shares of company stock valued at $140,095 over the last quarter. Insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in shares of Stoke Therapeutics by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after purchasing an additional 1,148 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after purchasing an additional 1,149 shares during the last quarter. Graham Capital Management L.P. boosted its holdings in shares of Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock worth $206,000 after purchasing an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock worth $1,021,000 after purchasing an additional 1,791 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock worth $414,000 after purchasing an additional 2,215 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.